Real-time regulatory updates from DEA, DOJ, FDA, CMS, and all 50 state medical boards — curated and analyzed by AI, reviewed by compliance experts. Built to help you stay ahead of healthcare regulation changes.
All 50 States + DC
350+ Regulatory Topics
Regulatory Intelligence Feed
0 articles published
Guides & Templates
In-Depth Compliance Resources
Comprehensive guides, checklists, and templates to help you navigate healthcare compliance — from CPOM structuring to GFE requirements and medical director agreements.
Our AI-powered intelligence engine monitors DEA, DOJ, FDA, CMS, and all 50 state medical boards so you never miss a compliance update that affects your business.
The FDA has announced a Class II recall for Semaglutide 5mg/mL and Glycine 25mg/mL multi-dose vials manufactured by Apollo Care, LLC. This nationwide recall, initiated due to the presence of particulate matter, affects product NDC 71170-712-03 and requires immediate attention from healthcare providers.
The FDA has issued a warning to compounders, urging them to cease using dietary supplement-grade glutathione in products intended for intravenous injection. This alert comes in response to at least 30 reported adverse events linked to IV glutathione, emphasizing the critical importance of using appropriate ingredient grades for sterile compounded preparations. Compounders who received this ingredient from Medisca are specifically instructed to contact customers and discontinue its use.
The U.S. Food and Drug Administration (FDA) has announced a Class II recall for a specific lot of SEMAGLUTIDE 12.5MG (2.5MG/mL), 5 mL Sterile Multi-Dose Vial, manufactured by Apollo Care, LLC. The recall was initiated due to the presence of particulate matter, specifically identified as nylon/polyamide and silk/proteinaceous-type material, in the injectable product. This nationwide recall, initiated on July 29, 2026, is ongoing and affects products distributed across the United States.
The FDA has announced a Class II recall for a compounded Semaglutide product, 10mg (5mg/mL) in a 2 mL sterile multi-dose vial, distributed nationwide. Initiated by Apollo Care, LLC, the recall is due to the presence of particulate matter identified as nylon/polyamide and silk/proteinaceous-type material. This ongoing action underscores critical safety considerations for injectable medications.
The U.S. Department of Justice (DOJ) has issued a memorandum outlining the enforcement priorities and organizational structure of its National Fraud Enforcement Division (the Fraud Division). This detailed roadmap emphasizes data analytics, nationwide coordination, and a broad mandate to investigate and prosecute fraud, including a specific focus on healthcare fraud and telemedicine schemes.
Monogram Health, a Medicare Advantage provider, has agreed to pay $24 million to resolve allegations that it violated the False Claims Act. The settlement addresses claims that the company submitted false diagnosis codes to improperly increase Medicare Advantage payments from January 2021 through December 2023.
The Department of Justice and the Drug Enforcement Administration have announced a $50 million settlement with Walmart Inc. to resolve allegations that its pharmacies illegally filled thousands of invalid prescriptions for opioids and other controlled substances. The settlement addresses Walmart's alleged failures in preventing the diversion of controlled substances, including prioritizing sales over compliance and ignoring pharmacists' warnings about "pill mills" and red flag prescriptions. In addition to the monetary penalty, Walmart has agreed to implement new compliance obligations to strengthen its oversight of controlled substance dispensing.
The Drug Enforcement Administration (DEA) has issued a temporary order placing four synthetic opioids—5,6-dichloro brorphine, 5,6-dichloro desmethylchlorphine, N-propionitrile chlorphine, and spirochlorphine—into Schedule I of the Controlled Substances Act (CSA). This action is based on a finding of an imminent hazard to public safety and subjects handlers of these substances to strict regulatory controls and sanctions. The temporary scheduling is effective for two years, from August 27, 2026, until August 27, 2028.
The Drug Enforcement Administration (DEA) has issued an interim final rule placing cipepofol, marketed as Cypsedo, into Schedule IV of the Controlled Substances Act (CSA). This action follows the United States Food and Drug Administration's (FDA) approval of Cypsedo for general anesthesia and a scheduling recommendation from the Department of Health and Human Services (HHS). The rule is effective immediately, with a public comment period open until September 28, 2026.
The Department of Justice (DOJ) has reinforced its commitment to combating healthcare fraud, explicitly identifying telemedicine fraud as a key enforcement priority. This commitment is underscored by the sentencing of a former owner of telemedicine companies in Boston for a $110 million Medicare fraud scheme involving medically unnecessary durable medical equipment (DME). The action demonstrates the government's focus on deterring fraudulent activities across the healthcare sector, particularly within telehealth services.
The Department of Justice (DOJ) has announced a two-year prison sentence for a former owner of two Boston-based telemedicine companies, who was involved in a $110 million Medicare fraud scheme. This case highlights the DOJ's ongoing commitment to prosecuting healthcare fraud, particularly within the rapidly expanding telemedicine sector, focusing on medically unnecessary services and equipment.
Maine's Department of Health and Human Services (DHHS), Office of MaineCare Services, has proposed amendments to Chapter III, Section 20 of the MaineCare Benefits Manual (MBM). These changes establish reimbursement methodology for new home and community-based services (HCBS) and shift the publication of reimbursement rates to the Department's website, requiring legislative approval to become legally effective.
Optimal Balance Pharmacy has initiated a voluntary nationwide recall of specific lots of its Compounded Glutathione 200 mg/mL Multi-Dose Vials. The recall is due to identified elevated bacterial endotoxin levels, which pose a significant risk of adverse medical events, including life-threatening reactions.
Federal authorities are intensifying efforts against healthcare fraud, with the HHS Office of Inspector General (OIG) indicating a broader, coordinated crackdown across various fraud types. Concurrently, the Department of Justice (DOJ) has established its National Fraud Enforcement Division (NFED) to deploy significant resources and advanced analytics for more efficient detection and prosecution of fraud against federal programs.
The Department of Justice has unsealed an indictment charging four individuals, members of a Bronx-based racketeering organization known as the 'War Room,' with racketeering, fraud, narcotics, and money laundering offenses. The charges stem from an alleged scheme to defraud Medicaid of over $12 million by fabricating transportation data for patients attending methadone clinics, alongside paying kickbacks and engaging in violent acts to protect the criminal enterprise. This case highlights aggressive federal enforcement against organized healthcare fraud and the exploitation of vulnerable patients.
